Reuters logo
BRIEF-Sanofi Pasteur and Medimmune collaborate on monoclonal antibody to prevent illnesses associated with RSV
March 3, 2017 / 7:36 AM / 7 months ago

BRIEF-Sanofi Pasteur and Medimmune collaborate on monoclonal antibody to prevent illnesses associated with RSV

March 3 (Reuters) - Sanofi:

* Sanofi Pasteur and Medimmune collaborate on monoclonal antibody to prevent illnesses associated with RSV

* Sanofi Pasteur will make an upfront payment of 120 million euros and pay up to 495 million euros upon achievement of certain development and sales-related milestones

* Two companies will share all costs and profits equally

* Medimmune will continue to lead all development activity up to first approval, and AstraZeneca will retain medi8897 manufacturing activities

* Sanofi Pasteur will lead commercialization activities for medi8897 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below